This week, the ratings of nine biotechnology stocks on Portfolio Grader are down. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
EPIRUS Biopharmaceuticals, Inc.’s (EPRS) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. For Portfolio Grader’s specific subcategory of Earnings Revisions, EPRS also gets an F. For more information, get Portfolio Grader’s complete analysis of EPRS stock.
Slipping from a C to a D rating, Ohr Pharmaceutical Inc (OHRP) takes a hit this week. Ohr Pharmaceutical develops pharmaceuticals for wound care and to treat cachexia. The stock gets F’s in Earnings Revisions and Equity. To get an in-depth look at OHRP, get Portfolio Grader’s complete analysis of OHRP stock.
The rating of Trius Therapeutics, Inc. (TSRX) slips from a C to a D. Trius Therapeutics is a biopharmaceutical company. The stock receives F’s in Earnings Growth, Earnings Momentum and Equity. Cash Flow and Sales Growth also get F’s. For more information, get Portfolio Grader’s complete analysis of TSRX stock.
This week, Vical Incorporated (VICL) drops from a C to a D rating. Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The stock gets F’s in Equity and Cash Flow. To get an in-depth look at VICL, get Portfolio Grader’s complete analysis of VICL stock.
Tenax Therapeutics, Inc. (TENX) ratings are on the decline this week as the company earns an F (“strong sell”). Last week, it received a D (“sell”). The stock gets F’s in Earnings Momentum, Earnings Revisions and Equity. Cash Flow and Sales Growth also get F’s. The stock currently has a trailing PE Ratio of 106.30. For more information, get Portfolio Grader’s complete analysis of TENX stock.
Synergy Pharmaceuticals, Inc.’s (SGYP) rating weakens this week, dropping to an F versus last week’s D. Synergy Pharmaceuticals is a biopharmaceutical company focused on the development of drugs to treat gastrointestinal disorders and diseases. The stock gets F’s in Equity and Cash Flow. As of March 11, 2015, 14.3% of outstanding Synergy Pharmaceuticals, Inc. shares were held short. To get an in-depth look at SGYP, get Portfolio Grader’s complete analysis of SGYP stock.
This is a rough week for Verastem, Inc. (VSTM). The company’s rating falls to F from the previous week’s D. Verastem is a biopharmaceutical company which is focused on discovering and developing novel drugs that selectively target cancer stem cells in breast and other cancers along with proprietary companion diagnostics. The stock gets F’s in Equity and Cash Flow. Shares of the stock are changing hands at twice the rate they were a week ago. For more information, get Portfolio Grader’s complete analysis of VSTM stock.
Celldex Therapeutics, Inc. (CLDX) earns a D this week, moving down from last week’s grade of C. Celldex Therapeutics is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. The stock also gets an F in Equity. As of March 11, 2015, 23.7% of outstanding Celldex Therapeutics, Inc. shares were held short. To get an in-depth look at CLDX, get Portfolio Grader’s complete analysis of CLDX stock.
The rating of Trevena, Inc. (TRVN) slips from a C to a D. The stock gets F’s in Equity and Cash Flow. Shares of the stock are being traded at a very rapid pace, up 790.8% from the week prior. For more information, get Portfolio Grader’s complete analysis of TRVN stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
